DHEA at a glance
DHEA (dehydroepiandrosterone) is a steroid hormone that the adrenal glands release in large amounts and that tissues turn into androgens and oestrogens. As prasterone, it is the active substance of authorised medicines in the EU. In trials in young men who lifted weights and in older adults, DHEA added no strength or muscle compared with placebo. WADA names it as an anabolic steroid prohibited at all times, and UK law lists it as a Class C drug.
Evidence: Human trials · Updated 20 November 2026
What DHEA is
Dehydroepiandrosterone, or DHEA, is a steroid hormone. In humans, the adrenal glands release large amounts of it and of its sulfate form, DHEA-S. Tissues across the body convert both into androstenedione and then into active androgens and oestrogens. Adrenal output of DHEA-S falls markedly with age.
As a medicine, DHEA goes by the name prasterone. In the EU it is the active substance of Intrarosa, a prescription vaginal pessary for postmenopausal women with moderate to severe vulvar and vaginal atrophy. According to the European Medicines Agency, prasterone is converted there into oestrogens and androgens.
7-keto-DHEA, sold in separate products, is a different compound. WADA names it in the same class of anabolic steroids as DHEA.
How DHEA works
DHEA is a precursor: what it does depends on the hormones the body makes from it. A 2013 meta-analysis in older men linked the small effect of DHEA on body fat to its conversion into androgens and oestrogens.
In ten young men, a single serving raised blood androstenedione within an hour but left testosterone and oestrogen unchanged. In recreationally trained young adults, four weeks of DHEA raised blood DHEA, DHEA-S, androstenedione, testosterone, dihydrotestosterone and oestrone in both sexes. The rise in testosterone was more marked in the women than in the men.
Evidence
Young men in training. In a 1999 trial, 19 young men followed an eight-week whole-body resistance training programme with DHEA or placebo. DHEA did not raise free or total testosterone. Strength and lean body mass rose by similar amounts in both groups.
Older adults. A two-year placebo-controlled trial enrolled 87 older men and 57 older women with low DHEA-S. The men were split between DHEA, low-dose testosterone and placebo. DHEA had no significant effect on body composition and did not change aerobic capacity, muscle strength or insulin sensitivity. Quality of life did not improve. Bone density rose at the hip in the men taking DHEA and at the wrist in the women.
A 2013 meta-analysis pooled 25 placebo-controlled trials with 1,353 older men, followed for 36 weeks on average. DHEA was linked to a small drop in fat mass. That link disappeared once the rises in testosterone and oestradiol were taken into account. Blood fats, blood sugar, bone, sexual function and quality of life did not differ from placebo.
Women. In postmenopausal women with normal adrenal function, a 2014 meta-analysis of 23 trials with 1,188 women found no significant effect on libido or sexual function. Blood fats, blood sugar, weight and bone density did not change either, and the authors rated their confidence as low. In women with adrenal insufficiency, a 2009 meta-analysis of 10 trials found small gains in quality of life and depression scores. Anxiety and sexual well-being did not change significantly.
Drug testing. In a four-week placebo-controlled study in 11 young women and 10 young men, DHEA strongly altered the urinary steroid profile of every woman. The software behind the athlete biological passport flagged 10 of the 11 women’s profiles as atypical.
Side effects. In the eight-week trial in young men, liver enzymes and blood fats did not change. The two-year trial in older adults reported no major adverse effects. DHEA raises androgen and oestrogen levels, so talk to a doctor before using it, especially if you take medication or have a hormone-sensitive condition.
Amounts on labels
Two Hammer Labz labels list DHEA.
| Hammer Labz product | Name on the label | Amount | Label serving |
|---|---|---|---|
| DHEA MAX | Dehydroepiandrosteron | 50 mg | 1 capsule |
| Trojan Test PRO | DHEA | 100 mg | 3 capsules |
Trojan Test PRO lists DHEA alongside 11 other ingredients, arimistane among them. Its formula also includes Ajuga turkestanica extract, the plant source of turkesterone, and tongkat ali.
DHEA is the active substance of authorised medicines in the EU, a Class C drug in the UK and an anabolic agent prohibited in sport. For substances like this, we give the label amount and the status and nothing more: no amounts from studies, no “typical” amounts and no conversions. Our method is on the how we review page.
Legal and anti-doping status
Status checked on 20 November 2026.
- WADA: the 2026 and 2027 Lists name prasterone (dehydroepiandrosterone, DHEA) in class S1.1, anabolic androgenic steroids, prohibited at all times. 7-keto-DHEA is named in the same class.
- UK: the Misuse of Drugs Act 1971 lists prasterone among the Class C drugs in Part III of Schedule 2.
- EU, medicines: prasterone is the active substance of medicines authorised in the EU. One of them, Intrarosa, has been authorised across the EU since 2018 and is available only with a prescription. In Poland, oral medicines with prasterone are also authorised, among them Biosteron and Stymen.
- EU, food: the EU novel food catalogue has no entry for DHEA, dehydroepiandrosterone or prasterone. A missing entry does not settle an ingredient’s status.
- US: federal law excludes dehydroepiandrosterone from its definition of anabolic steroids.
Not for drug-tested athletes: DHEA MAX and Trojan Test PRO list DHEA, which WADA names in class S1.1. Trojan Test PRO also lists arimistane, which WADA names in class S4.1, aromatase inhibitors; both classes are prohibited at all times. Status differs by country and changes over time.
Found in
Hammer Labz (brand page)
- DHEA MAX
- Trojan Test PRO
Haya Labs
- DHEA 25 mg (180 capsules)
- DHEA 50 mg (60 capsules and 180 capsules)
- DHEA 100 mg (60 capsules)
- DHEA 100 mg (180 tablets)
We have not seen the Haya Labs labels, so we give no amounts beyond the product names.
Sources
- Product labels: Hammer Labz supplement facts panels for DHEA MAX and Trojan Test PRO, as listed in November 2026.
- Labrie F, Bélanger A, Luu-The V, et al. (1998). DHEA and the intracrine formation of androgens and estrogens in peripheral target tissues: its role during aging. Steroids, 63(5–6), 322–328. PMID: 9618795.
- European Medicines Agency. Intrarosa: EPAR. Medicine overview and product details. Accessed 20 November 2026.
- Corona G, Rastrelli G, Giagulli VA, et al. (2013). Dehydroepiandrosterone supplementation in elderly men: a meta-analysis study of placebo-controlled trials. J Clin Endocrinol Metab, 98(9), 3615–3626. PMID: 23824417.
- Brown GA, Vukovich MD, Sharp RL, et al. (1999). Effect of oral DHEA on serum testosterone and adaptations to resistance training in young men. J Appl Physiol (1985), 87(6), 2274–2283. PMID: 10601178.
- Collomp K, Buisson C, Gravisse N, et al. (2018). Effects of short-term DHEA intake on hormonal responses in young recreationally trained athletes: modulation by gender. Endocrine, 59(3), 538–546. PMID: 29322301.
- Nair KS, Rizza RA, O’Brien P, et al. (2006). DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med, 355(16), 1647–1659. PMID: 17050889.
- Elraiyah T, Sonbol MB, Wang Z, et al. (2014). Clinical review: The benefits and harms of systemic dehydroepiandrosterone (DHEA) in postmenopausal women with normal adrenal function: a systematic review and meta-analysis. J Clin Endocrinol Metab, 99(10), 3536–3542. PMID: 25279571.
- Alkatib AA, Cosma M, Elamin MB, et al. (2009). A systematic review and meta-analysis of randomized placebo-controlled trials of DHEA treatment effects on quality of life in women with adrenal insufficiency. J Clin Endocrinol Metab, 94(10), 3676–3681. PMID: 19773400.
- Buisson C, Frelat C, Privat K, et al. (2018). Metabolic and isotopic signature of short-term DHEA administration in women: Comparison with findings in men. Drug Test Anal, 10(11–12), 1744–1754. PMID: 30315670.
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. In force from 1 January 2026. Accessed 20 November 2026.
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2027. In force from 1 January 2027. Accessed 20 November 2026.
- UK Government. Misuse of Drugs Act 1971, Schedule 2: Controlled drugs. Part III, Class C drugs. legislation.gov.uk. Accessed 20 November 2026.
- European Medicines Agency. Article 57 product data: medicines authorised in the EU and EEA. Data file updated 12 November 2026. Accessed 20 November 2026.
- European Commission. EU Novel Food status catalogue. Searches for DHEA, dehydroepiandrosterone and prasterone. Catalogue data retrieved 20 November 2026.
- U.S. Government Publishing Office. 21 U.S.C. 802: Definitions. United States Code, 2023 edition, paragraph (41)(A). Accessed 20 November 2026.
